Last update July 16, 2017
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C23H30O4 is Nomegestrol Acetate in Molecular formula.
Is written in other languages:Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 63 | % |
Molecular weight | 371 | daltons |
Protein Binding | 97 - 98 | % |
VD | 1.7 | l/Kg |
Tmax | 2 | hours |
T½ | 46 (28 - 83) | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Third generation synthetic progestogen which is structurally related to progesterone.
It has been used as a part of only-one-component contraceptives which have one year lasting effect for subdermal implants. Also orally used alone or associated to estrogen (see info on Estradiol + Nomegestrol).
In a study comparing effects on breastfeeding women (120 with a Nomegestrol implant and 120 with an intrauterine device (IUD), there were no significant differences on duration of breastfeeding nor somatic follow-up criteria nor health issues in infants (Abdel -Aleem 1996).
There is controversy about whether an early implant in the first few days after delivery affects milk production. Some authors consider it safer to wait for 4 to 6 weeks (ABM 2015).
Because there is less published experience than with other drugs in the same group, alternatives known as safer and of shorter half life may be preferable.
Progestogens in general are considered the contraceptive of choice during breastfeeding since they neither affect excretion and composition of the milk nor cause side effects nor affect the growth of the infants and the duration of lactation.
Progestogen implants are considered a good choice in women who are breastfeeding (Meckstroth 2001).
During lactation, progestogen-only contraceptives are preferred over those combined with estrogen. Otherwise, those with lower doses of estrogen should be used.
Within the first 6 weeks postpartum, non-hormonal contraceptive methods should be the first option. There is a controversy on whether milk production is decreased when progestogens are used prior breastfeeding is well established.
See below the information of these related products: